Sanofi scraps a PhII IL4/IL13 development program for lung scarring disease
Sanofi and Regeneron have scored big with the IL4/IL13 pathway, which has proved to be a blockbuster approach for their drug Dupixent (dupilumab). But Sanofi’s solo effort on a similar pathway approach for SAR156597 proved to be a flop.
The French pharma outfit noted in their Q3 release this morning that they are scrapping a mid-stage program for the IL4/13 drug SAR156597 in idiopathic pulmonary fibrosis, a lung scarring disease. There was no word on the reason why.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
